Vincent Yi-Fong Su1,2,3, Chia-Jen Liu4,2,5, Yu-Wen Hu6,5, Wei-Juin Su1,2, Yuh-Min Chen1,2, Shinn-Liang Lai1,2, Tzeng-Ji Chen7,2, Diahn-Warng Perng1,2, Yu-Chin Lee1,2, Cheng-Hwai Tzeng4,2, Kun-Ta Chou8,9,10. 1. Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 112, Taiwan. 2. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 4. Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Institute of Public Health, National Yang-Ming University, Taipei, Taiwan. 6. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan. 7. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 8. Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 112, Taiwan. ale1371@yahoo.com.tw. 9. School of Medicine, National Yang-Ming University, Taipei, Taiwan. ale1371@yahoo.com.tw. 10. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. ale1371@yahoo.com.tw.
Abstract
BACKGROUND: The association between amyloidosis and cancer remains unclear. PARTICIPANTS AND METHODS: Using the Taiwan National Health Insurance Research Database we conducted a population-based cohort study. Patients newly diagnosed with amyloidosis between 1997 and 2009 were enrolled. Patients with antecedent cancer were excluded. Standardized incidence ratios (SIR) of cancers were calculated for the study cohort and compared with cancer incidence among the general population. We used a multivariate Cox regression model to evaluate the predictors of cancer development for patients with amyloidosis. RESULTS: The study included 1,693 subjects with median follow-up of 5.63 years. A total of 68 patients developed cancer. The incidence of kidney cancer (SIR 3.42; 95 % CI 1.11-7.97; p = 0.034) and hematologic malignancies (SIR 3.88; 95 % CI 1.86-7.14; p < 0.001) were significantly higher for patients with amyloidosis. CONCLUSION: This is currently the largest study to evaluate cancer risk among patients with amyloidosis. The results indicate that amyloidosis may be associated with an increased risk of kidney cancer and hematologic malignancies.
BACKGROUND: The association between amyloidosis and cancer remains unclear. PARTICIPANTS AND METHODS: Using the Taiwan National Health Insurance Research Database we conducted a population-based cohort study. Patients newly diagnosed with amyloidosis between 1997 and 2009 were enrolled. Patients with antecedent cancer were excluded. Standardized incidence ratios (SIR) of cancers were calculated for the study cohort and compared with cancer incidence among the general population. We used a multivariate Cox regression model to evaluate the predictors of cancer development for patients with amyloidosis. RESULTS: The study included 1,693 subjects with median follow-up of 5.63 years. A total of 68 patients developed cancer. The incidence of kidney cancer (SIR 3.42; 95 % CI 1.11-7.97; p = 0.034) and hematologic malignancies (SIR 3.88; 95 % CI 1.86-7.14; p < 0.001) were significantly higher for patients with amyloidosis. CONCLUSION: This is currently the largest study to evaluate cancer risk among patients with amyloidosis. The results indicate that amyloidosis may be associated with an increased risk of kidney cancer and hematologic malignancies.
Entities:
Keywords:
Amyloidosis; Cancer; Hematologic malignancies; Kidney cancer
Authors: S Caulet; I Robert; E Bardaxoglou; P Noret; P Tas; Y Le Prise; B Launois; M P Ramee Journal: Pathol Res Pract Date: 1995-12 Impact factor: 3.250
Authors: Sanghui Park; Hyun Yee Cho; Seung Yeon Ha; Dong Hae Chung; Na Rae Kim; Jung Suk An Journal: J Korean Med Sci Date: 2011-04-21 Impact factor: 2.153